Repositive appoints Slaven Stekovic as Head of Strategic Growth and leading commercial advisers to drive the company’s scale-up and global growth ambitions

Repositive – the Cambridge-based startup that connects researchers with the right preclinical cancer models for their research – today announced the appointment of Slaven Stekovic as Head of Strategic Growth, along with leading commercial experts (Mariana Vaschetto and Francesca Crawford) to its advisory board, to drive the company’s scale-up and global growth ambitions within the pharma and biotech market.

Coulter Partners secures Non-Executive Director for Nanoform

Coulter Partners was very pleased to partner once more with innovative medicine enabling nanotechnology company, Nanoform to secure the appointment of Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.

IQVIA joins landmark UK health data digital initiative

IQVIA will deliver technology and capabilities to support DATA-CAN, the new national Health Data Research Hub for Cancer, to improve outcomes for NHS cancer patients.

CEO Update | Monday 16 September 2019

Last week hidden beneath the Government's announcement that students will be able to stay in the UK for two years, there were developments on the UK life science industrial strategy, which the BIA has partnered with government on for the last three years. 

Smelling the disease - Nosing our way towards earlier diagnosis and new biomarkers

Could the sense of smell drive future biological detection methods? In university and drug company labs which develop assays for diseases and for measuring drug effects, you will find a range of readers for measuring changes in biological systems.

Guest blog | UK Synthetic Biology Startup Survey - 2019

Stephen Chambers, founder of the Subsero and Entrepreneur in Residence at the Royal Society, breaks down the trends in the UK’s synthetic biology start-up community.

CEO Update | Monday 09 September 2019

The BIA has signed a major deal in China, enabling UK life Science companies to gain an effective first landing place in this exciting and innovative market.  Chair of the BIA, Dr Jane Osbourn OBE attended the opening ceremony of the Wuxi International Life-science Innovation Campus (I-Campus), where a memorandum of understanding was signed between the I-campus, the BIA and AstraZeneca. This is a key initiative for the BIA to make it easier for UK life sciences SMEs to do business in China.

Mogrify appoints Dr. Jane Osbourn, OBE as Chair

Cambridge, UK, 9th September 2019: Mogrify Ltd (Mogrify), a UK company aiming to transform the development of cell therapies, today announced the appointment of Dr. Jane Osbourn, OBE as Chair of the Board. In addition to this role, Dr. Osbourn will become a Member of the Scientific Advisory Board and support the Company’s executive team in therapeutic program selection, industrial partner development, mentoring and investor relations.

BIA announces major initiative with AstraZeneca and new state of the art lifescience innovation campus in Wuxi China

The BioIndustry Association (BIA) has signed a memorandum of understanding with the Wuxi International Life-science Innovation Campus (I-Campus) and AstraZeneca in China. The state-of-the-art campus will enable UK SMES companies to easily explore, partner and engage with China’s rapidly expanding healthcare innovation market. The I-campus will also serve as AstraZeneca’s new China headquarters.

Lightcast Discovery Set to Deliver Step-change in Complex Cell Analysis, Raises £1.3m in Seed Financing to Expand Pilot Studies

Cambridge, UK, 9 September 2019 – Lightcast Discovery Ltd (“Lightcast”), an early stage developer of a next-generation microfluidic platform aiming to revolutionise complex cell analysis, today announces that it has raised £1.3 m (USD 1.6m) in seed financing from private investors to develop the capabilities and applications of its platform including continuing to expand its range of pilot studies.